Cepi expands partnership with valneva with a $41.3 million grant to support broader access to the world's first chikungunya vaccine

Oslo, norway, and saint-herblain, france, july 22, 2024—the coalition for epidemic preparedness innovations (cepi) and valneva se (nasdaq: valn; euronext paris: vla), a specialty vaccine company, have expanded their partnership to support broader access to the world's first chikungunya vaccine, ixchiq®, in low- and middle-income countries (lmics), as well as post-marketing trials and potential label extensions in children, adolescents and pregnant women.
VALN Ratings Summary
VALN Quant Ranking